Clinical and molecular features of younger adult patients with cytogenetically normal AML (N = 365)
| Characteristic . | Summary statistics . |
|---|---|
| Age, y | |
| Median | 46 |
| Range | 17-59 |
| Sex, n (%) | |
| Male | 188 (52) |
| Female | 177 (48) |
| Race, n (%) | |
| White | 324 (91) |
| Nonwhite | 34 (9) |
| Hemoglobin, g/dL | |
| Median | 9.2 |
| Range | 4.2-25.1 |
| Platelet count, ×109/L | |
| Median | 56 |
| Range | 8-445 |
| WBC count, ×109/L | |
| Median | 28.8 |
| Range | 0.6-475.0 |
| Blood blasts, % | |
| Median | 60 |
| Range | 0-97 |
| BM blasts, % | |
| Median | 68 |
| Range | 18-96 |
| Extramedullary involvement, n (%) | |
| Present | 106 (30) |
| Absent | 250 (70) |
| ASXL1, n (%) | |
| Mutated | 12 (3) |
| Wild type | 334 (97) |
| CEBPA, n (%) | |
| Double mutated | 54 (16) |
| Wild type | 294 (84) |
| DNMT3A, n (%) | |
| Mutated | 139 (39) |
| R882 | 105 |
| Non-R882 | 34 |
| Wild type | 213 (61) |
| FLT3-ITD, n (%) | |
| Present | 137 (38) |
| Absent | 221 (62) |
| FLT3-TKD, n (%) | |
| Present | 36 (10) |
| Absent | 314 (90) |
| IDH1, n (%) | |
| Mutated | 27 (8) |
| Wild type | 325 (92) |
| IDH2, n (%) | |
| Mutated | 34 (10) |
| Wild type | 318 (90) |
| NPM1, n (%) | |
| Mutated | 201 (58) |
| Wild type | 143 (42) |
| RUNX1, n (%) | |
| Mutated | 19 (5) |
| Wild type | 333 (95) |
| SF1, n (%) | |
| Mutated | 2 (1) |
| Wild type | 350 (99) |
| SF3A1, n (%) | |
| Mutated | 1 (0) |
| Wild type | 351 (100) |
| SF3B1, n (%) | |
| Mutated | 10 (3) |
| Wild type | 342 (97) |
| SRSF2, n (%) | |
| Mutated | 11 (3) |
| Wild type | 339 (97) |
| TET2, n (%) | |
| Mutated | 40 (11) |
| Wild type | 312 (89) |
| U2AF1, n (%) | |
| Mutated | 4 (1) |
| Wild type | 348 (99) |
| U2AF2, n (%) | |
| Mutated | 0 (0) |
| Wild type | 352 (100) |
| WT1, n (%) | |
| Mutated | 39 (11) |
| Wild type | 313 (89) |
| ZRSR2, n (%) | |
| Mutated | 15 (4) |
| Wild type | 337 (96) |
| ELN genetic group*, n (%) | |
| Favorable | 199 (59) |
| Intermediate | 88 (26) |
| Adverse | 52 (15) |
| NPM1 and DNMT3A, n (%) | |
| Either or neither mutated | 239 (69) |
| Both mutated | 105 (31) |
| NPM1 and FLT3-ITD, n (%) | |
| Either or neither mutated | 252 (74) |
| Both mutated | 89 (26) |
| ERG expression group†, n (%) | |
| High | 184 (51) |
| Low | 178 (49) |
| BAALC expression group†, n (%) | |
| High | 168 (50) |
| Low | 166 (50) |
| MN1 expression group†, n (%) | |
| High | 176 (50) |
| Low | 173 (50) |
| miR-181a expression group†, n (%) | |
| High | 148 (50) |
| Low | 147 (50) |
| miR-3151, n (%) | |
| Expressed | 51 (17) |
| Not expressed | 244 (83) |
| miR-155 expression group†, n (%) | |
| High | 147 (50) |
| Low | 148 (50) |
| Characteristic . | Summary statistics . |
|---|---|
| Age, y | |
| Median | 46 |
| Range | 17-59 |
| Sex, n (%) | |
| Male | 188 (52) |
| Female | 177 (48) |
| Race, n (%) | |
| White | 324 (91) |
| Nonwhite | 34 (9) |
| Hemoglobin, g/dL | |
| Median | 9.2 |
| Range | 4.2-25.1 |
| Platelet count, ×109/L | |
| Median | 56 |
| Range | 8-445 |
| WBC count, ×109/L | |
| Median | 28.8 |
| Range | 0.6-475.0 |
| Blood blasts, % | |
| Median | 60 |
| Range | 0-97 |
| BM blasts, % | |
| Median | 68 |
| Range | 18-96 |
| Extramedullary involvement, n (%) | |
| Present | 106 (30) |
| Absent | 250 (70) |
| ASXL1, n (%) | |
| Mutated | 12 (3) |
| Wild type | 334 (97) |
| CEBPA, n (%) | |
| Double mutated | 54 (16) |
| Wild type | 294 (84) |
| DNMT3A, n (%) | |
| Mutated | 139 (39) |
| R882 | 105 |
| Non-R882 | 34 |
| Wild type | 213 (61) |
| FLT3-ITD, n (%) | |
| Present | 137 (38) |
| Absent | 221 (62) |
| FLT3-TKD, n (%) | |
| Present | 36 (10) |
| Absent | 314 (90) |
| IDH1, n (%) | |
| Mutated | 27 (8) |
| Wild type | 325 (92) |
| IDH2, n (%) | |
| Mutated | 34 (10) |
| Wild type | 318 (90) |
| NPM1, n (%) | |
| Mutated | 201 (58) |
| Wild type | 143 (42) |
| RUNX1, n (%) | |
| Mutated | 19 (5) |
| Wild type | 333 (95) |
| SF1, n (%) | |
| Mutated | 2 (1) |
| Wild type | 350 (99) |
| SF3A1, n (%) | |
| Mutated | 1 (0) |
| Wild type | 351 (100) |
| SF3B1, n (%) | |
| Mutated | 10 (3) |
| Wild type | 342 (97) |
| SRSF2, n (%) | |
| Mutated | 11 (3) |
| Wild type | 339 (97) |
| TET2, n (%) | |
| Mutated | 40 (11) |
| Wild type | 312 (89) |
| U2AF1, n (%) | |
| Mutated | 4 (1) |
| Wild type | 348 (99) |
| U2AF2, n (%) | |
| Mutated | 0 (0) |
| Wild type | 352 (100) |
| WT1, n (%) | |
| Mutated | 39 (11) |
| Wild type | 313 (89) |
| ZRSR2, n (%) | |
| Mutated | 15 (4) |
| Wild type | 337 (96) |
| ELN genetic group*, n (%) | |
| Favorable | 199 (59) |
| Intermediate | 88 (26) |
| Adverse | 52 (15) |
| NPM1 and DNMT3A, n (%) | |
| Either or neither mutated | 239 (69) |
| Both mutated | 105 (31) |
| NPM1 and FLT3-ITD, n (%) | |
| Either or neither mutated | 252 (74) |
| Both mutated | 89 (26) |
| ERG expression group†, n (%) | |
| High | 184 (51) |
| Low | 178 (49) |
| BAALC expression group†, n (%) | |
| High | 168 (50) |
| Low | 166 (50) |
| MN1 expression group†, n (%) | |
| High | 176 (50) |
| Low | 173 (50) |
| miR-181a expression group†, n (%) | |
| High | 148 (50) |
| Low | 147 (50) |
| miR-3151, n (%) | |
| Expressed | 51 (17) |
| Not expressed | 244 (83) |
| miR-155 expression group†, n (%) | |
| High | 147 (50) |
| Low | 148 (50) |
ELN, European LeukemiaNet; WBC, white blood cell count.
Among patients with CN-AML, the ELN favorable-risk category comprises patients with double-mutated CEBPA and patients with mutated NPM1 without FLT3-ITD or with FLT3-ITDlow. The ELN intermediate-risk category includes patients with wild-type or single-mutated CEBPA, patients with wild-type NPM1 without FLT3-ITD or with FLT3-ITDlow, and/or patients with mutated NPM1 and FLT3-ITDhigh. The ELN adverse-risk category comprises patients with wild-type or single-mutated CEBPA and wild-type NPM1 with FLT3-ITDhigh, patients with mutated RUNX1 and/or ASXL1 (if these mutations do not co-occur with favorable-risk subtypes), and/or patients with mutated TP53. FLT3-ITDlow is defined by an FLT3-ITD/FLT3 wild-type allelic ratio of <0.5, and FLT3-ITDhigh is defined by an FLT3-ITD/FLT3 wild-type allelic ratio of ≥0.5.
The median expression value was used as a cut point.